ElectroCore to Buy NeuroMetrix, Adding Quell Platform

Dow Jones12-18

By Josh Beckerman

ElectroCore, a bioelectronic medicine and wellness company, agreed to buy NeuroMetrix, predicting the addition of the Quell platform will help its earnings and diversify its nerve stimulation product offerings.

The wearable Quell neuromodulator helps reduce fibromyalgia symptoms.

NeuroMetrix expects to divest its DPNCheck platform, which won't be included in the sale. The DPNCheck product is a rapid point-of-care test for peripheral neuropathies.

The exact deal price hasn't been determined.

ElectroCore will buy NeuroMetrix shares for the equivalent of NeuroMetrix's balance of net cash at the closing, after deduction of certain management compensation payments and other severance costs, transaction expenses and other accrued liabilities.

Consideration will also include contingent value rights for certain future net proceeds from any divestiture of DPNCheck that is completed prior to the closing, and certain royalties related to Quell sales.

NeuroMetrix shares rose 9.8% to $4.14 after hours Tuesday. Shares of electroCore rose 5.5% to $14.70.

NeuroMetrix said in February that it would review strategic options. At the time it said, "There are attractive opportunities for both vertical and horizontal growth" for Quell technology. It also said it was reviewing the DPNCheck business "in light of the fundamental Medicare Advantage risk adjustment changes implemented by CMS last year."

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

December 17, 2024 18:41 ET (23:41 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492917843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 07:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492917843","market":"sg","top_or_hot":-1,"title":"ElectroCore to Buy NeuroMetrix, Adding Quell Platform","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  ElectroCore, a bioelectronic medicine and wellness company, agreed to buy <a href=\"https://laohu8.com/S/NURO\">NeuroMetrix</a>, predicting the addition of the Quell platform will help its earnings and diversify its nerve stimulation product offerings. \n</p>\n<p>\n  The wearable Quell neuromodulator helps reduce fibromyalgia symptoms. \n</p>\n<p>\n  NeuroMetrix expects to divest its DPNCheck platform, which won't be included in the sale. The DPNCheck product is a rapid point-of-care test for peripheral neuropathies. \n</p>\n<p>\n  The exact deal price hasn't been determined. \n</p>\n<p>\n  ElectroCore will buy NeuroMetrix shares for the equivalent of NeuroMetrix's balance of net cash at the closing, after deduction of certain management compensation payments and other severance costs, transaction expenses and other accrued liabilities. \n</p>\n<p>\n  Consideration will also include contingent value rights for certain future net proceeds from any divestiture of DPNCheck that is completed prior to the closing, and certain royalties related to Quell sales. \n</p>\n<p>\n  NeuroMetrix shares rose 9.8% to $4.14 after hours Tuesday. Shares of electroCore rose 5.5% to $14.70. \n</p>\n<p>\n  NeuroMetrix said in February that it would review strategic options. At the time it said, \"There are attractive opportunities for both vertical and horizontal growth\" for Quell technology. It also said it was reviewing the DPNCheck business \"in light of the fundamental Medicare Advantage risk adjustment changes implemented by CMS last year.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 18:41 ET (23:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ElectroCore to Buy NeuroMetrix, Adding Quell Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElectroCore to Buy NeuroMetrix, Adding Quell Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 07:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\n  ElectroCore, a bioelectronic medicine and wellness company, agreed to buy NeuroMetrix, predicting the addition of the Quell platform will help its earnings and diversify its...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ECOR","symbol_name":"Electrocore LLC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492917843","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492917843","pubTimestamp":1734478860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ElectroCore, a bioelectronic medicine and wellness company, agreed to buy NeuroMetrix, predicting the addition of the Quell platform will help its earnings and diversify its nerve stimulation product offerings.The wearable Quell neuromodulator helps reduce fibromyalgia symptoms.NeuroMetrix expects to divest its DPNCheck platform, which won't be included in the sale. The DPNCheck product is a rapid point-of-care test for peripheral neuropathies.ElectroCore will buy NeuroMetrix shares for the equivalent of NeuroMetrix's balance of net cash at the closing, after deduction of certain management compensation payments and other severance costs, transaction expenses and other accrued liabilities.Consideration will also include contingent value rights for certain future net proceeds from any divestiture of DPNCheck that is completed prior to the closing, and certain royalties related to Quell sales.NeuroMetrix shares rose 9.8% to $4.14 after hours Tuesday. Shares of electroCore rose 5.5% to $1","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ECOR":"Electrocore LLC","BK4082":"医疗保健设备","NURO":"NeuroMetrix"},"translate_title":"ElectroCore收购NeuroMetrix，增加Quell平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NURO":1,"ECOR":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  ElectroCore, a bioelectronic medicine and wellness company, agreed to buy NeuroMetrix, predicting the addition of the Quell platform will help its earnings and diversify its nerve stimulation product offerings. \n\n\n  The wearable Quell neuromodulator helps reduce fibromyalgia symptoms. \n\n\n  NeuroMetrix expects to divest its DPNCheck platform, which won't be included in the sale. The DPNCheck product is a rapid point-of-care test for peripheral neuropathies. \n\n\n  The exact deal price hasn't been determined. \n\n\n  ElectroCore will buy NeuroMetrix shares for the equivalent of NeuroMetrix's balance of net cash at the closing, after deduction of certain management compensation payments and other severance costs, transaction expenses and other accrued liabilities. \n\n\n  Consideration will also include contingent value rights for certain future net proceeds from any divestiture of DPNCheck that is completed prior to the closing, and certain royalties related to Quell sales. \n\n\n  NeuroMetrix shares rose 9.8% to $4.14 after hours Tuesday. Shares of electroCore rose 5.5% to $14.70. \n\n\n  NeuroMetrix said in February that it would review strategic options. At the time it said, \"There are attractive opportunities for both vertical and horizontal growth\" for Quell technology. It also said it was reviewing the DPNCheck business \"in light of the fundamental Medicare Advantage risk adjustment changes implemented by CMS last year.\" \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 18:41 ET (23:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492917843"}